Taysha Gene Therapies, Inc. (TSHA): Nasdaq/NYSE listing notice — Taysha Gene Therapies receives Nasdaq bid price deficiency notice; board changes announced

Taysha Gene Therapies, Inc.

Received Nasdaq notice on April 25, 2023 for minimum bid price below $1.00 for 30 consecutive days.
Has 180 days until October 23, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not cured, may transfer to Nasdaq Capital Market for additional 180-day grace period; failure could lead to delisting.
Director Kathleen Reape resigned effective Nov 1, 2023 due to employer guidelines; Board to appoint successor.
Board reconstituted with six directors; Reape moves from Class III to Class I to allow shareholder vote in 2024.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Kathleen Reape

Class I Director

TSHA · Taysha Gene Therapies, Inc.

Filed: April 27, 2023, 7:59 PM ET

Effective immediately prior to the conclusion of the 2023 Annual Meeting of Stockholders (the “ Annual Meeting ”), the Company expects that Dr. Reape will resign as a Class III director of the Company. Upon her resignation, the Board intends to appoint Dr. Reape as a Class I director of the Company to serve until the 2024 annual meeting of stockholders.

Departed

Kathleen Reape

Director

TSHA · Taysha Gene Therapies, Inc.

Effective: 2023-11-01
Filed: April 27, 2023, 7:59 PM ET

Kathleen Reape provided notice to the board of directors (the “ Board ”) of the Company of her decision to resign from the Board, effective November 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Taysha Gene Therapies, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 25, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) received a notice from The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until October 23, 2023, to regain compliance with the minimum bid price requirement. To regai

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kathleen Reape was appointed as Class I Director at Taysha Gene Therapies, Inc..

Action: appointed as Class I director
Role: Class I Director

Exact text from the filing

Effective immediately prior to the conclusion of the 2023 Annual Meeting of Stockholders (the “ Annual Meeting ”), the Company expects that Dr. Reape will resign as a Class III director of the Company. Upon her resignation, the Board intends to appoint Dr. Reape as a Class I director of the Company to serve until the 2024 annual meeting of stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kathleen Reape resigned as Director at Taysha Gene Therapies, Inc..

Action: resigned
Role: Director

Exact text from the filing

Kathleen Reape provided notice to the board of directors (the “ Board ”) of the Company of her decision to resign from the Board, effective November 1, 2023.

View on SEC.gov

Browse all listing & compliance notices →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-122129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.